Yonsa and Zytiga have different dosing and food effects.

Yonsa (abiraterone acetate) from Sun Pharma is a unique, ultramicrosize (smaller particle size) formulation of the oral CYP17 inhibitor abiraterone acetate (approved as Zytiga). Sun Pharma's Yonsa is approved to be used in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Yonsa contains the same active ingredient of Zytiga, also used to treat prostate cancer. Abiraterone acetate is converted in the body to abiraterone.

• The recommended dose of Yonsa for the treatment of patients with metastatic castration-resistant prostate cancer is 500 mg (four 125 mg tablets) given by mouth once daily in combination with oral methylprednisolone 4 mg twice daily.
• The recommended dose of Zytiga is 1,000 mg (two 500 mg tablets or four 250 mg tablets) by mouth once daily with prednisone 5 mg by mouth twice daily.
• In a previous study of healthy volunteers, a dose of Yonsa 500 mg was found to be bioequivalent to a 1000 mg dose of Zytiga.
• Patients with liver disease may require a lower dose or may not be able to use Yonsa or Zytiga.
• Zytiga must be taken on an empty stomach, either one hour before or two hours after a meal. However, Yonsa tablets can be taken with or without food. For both products, the tablets should be swallowed whole with water, and do not crush or chew tablets.